drug
PREGABALIN
Marketedupdated 3mo agoby RK Pharma Inc
Approvedannual revenue · 2024–2024peak $383M
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval58 co-mentions · 29 sources
- drugpregabalin ER29 co-mentions · 29 sources
- drugLyrica29 co-mentions · 29 sources
- drugpregabalin CR29 co-mentions · 29 sources
- tagSmall Molecule29 co-mentions · 29 sources
- drugpregabalin SR29 co-mentions · 29 sources
- companyLupin Ltd3 co-mentions · 3 sources
- companyStrides Pharma Inc3 co-mentions · 3 sources
all catalysts(14)
approval · 14
Apr 13, 2021
approval
PREGABALIN — FDA approval
PREGABALIN
→
Apr 13, 2021
approval
PREGABALIN — FDA approval
PREGABALIN
→
Mar 8, 2022
approval
PREGABALIN — FDA approval
PREGABALIN
→
May 3, 2022
approval
PREGABALIN — FDA approval
PREGABALIN
→
Apr 26, 2023
approval
PREGABALIN — FDA approval
PREGABALIN
→
Jul 21, 2023
approval
PREGABALIN — FDA approval
PREGABALIN
→
May 30, 2024
approval
PREGABALIN — FDA approval
PREGABALIN
→
Dec 9, 2024
approval
PREGABALIN — FDA approval
PREGABALIN
→
Sep 30, 2025
approval
PREGABALIN — FDA approval
PREGABALIN
→
Feb 2, 2026
approval
PREGABALIN — FDA approval
PREGABALIN
→
Feb 3, 2026
approval
PREGABALIN — FDA approval
PREGABALIN
→
Feb 23, 2026
approval
PREGABALIN — FDA approval
PREGABALIN
→
Feb 23, 2026
approval
PREGABALIN — FDA approval
PREGABALIN
→
Mar 30, 2026
approval
PREGABALIN — FDA approval
PREGABALIN
→
Trials studying PREGABALIN
- phase1Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants
- phase2Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
- phase1A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain
- phase2Y-4 to Treat the Postherpetic Neuralgia
- phase3Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
- —A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- phase2Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
- EP1Pharmacodynamic Study of 300mg Pregabalin vs Placebo in Healthy Male Adults
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 2, 2026
79 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- May 2, 2027patentUS 10022447*PED260d
- May 2, 2027patentUS 10022447*PED260d
- May 2, 2027patentUS 10022447*PED260d
- May 2, 2027patentUS 8945620*PED260d
- May 2, 2027patentUS 8945620*PED260d
- May 2, 2027patentUS 8945620*PED260d
- May 2, 2027patentUS 9144559*PED260d
- May 2, 2027patentUS 9144559*PED260d
- May 2, 2027patentUS 9144559*PED260d
- Nov 2, 2026method-of-use (U-2136)US 1002244779d
- Nov 2, 2026method-of-use (U-2136)US 1002244779d
- Nov 2, 2026method-of-use (U-2136)US 1002244779d
- Nov 2, 2026formulationUS 894562079d
- Nov 2, 2026formulationUS 894562079d
- Nov 2, 2026formulationUS 894562079d
- Nov 2, 2026formulationUS 914455979d
- Nov 2, 2026formulationUS 914455979d
- Nov 2, 2026formulationUS 914455979d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that